Correspondence 0001193125-25-006193 from Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc.
Date: Jan. 14, 2025 · CIK: 0001750149 · Accession: 0001193125-25-006193
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284222
Letter
Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway SE, Suite 1900
Atlanta, GA 30339
January 14, 2025
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Joshua Gorsky
Re: Inhibikase Therapeutics, Inc.
Registration Statement on Form S-3
Filed January 10, 2025
File No. 333-284222
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Inhibikase Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-284222) (the “Registration Statement”) be accelerated so that the Registration Statement will become effective on Thursday, January 16, 2025 at 4:30 p.m. (Eastern Time), or as soon thereafter as practicable.
Please feel free to direct any questions or comments concerning this request to Marishka DeToy, Esq. of Goodwin Procter LLP at (617) 570-1926.
The Company understands that the staff of the United States Securities and Exchange Commission will consider this request as confirmation by the Company that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
INHIBIKASE THERAPEUTICS, INC.
By:
/s/ Milton H. Werner, Ph.D.
Name:
Milton H. Werner, Ph.D.
Title:
President and Chief Executive Officer
cc:
Danielle Lauzon, Goodwin Procter LLP
Marishka DeToy, Goodwin Procter LLP
Show Raw Text
CORRESP 1 filename1.htm CORRESP Inhibikase Therapeutics, Inc. 3350 Riverwood Parkway SE, Suite 1900 Atlanta, GA 30339 January 14, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Joshua Gorsky Re: Inhibikase Therapeutics, Inc. Registration Statement on Form S-3 Filed January 10, 2025 File No. 333-284222 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Inhibikase Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-284222) (the “Registration Statement”) be accelerated so that the Registration Statement will become effective on Thursday, January 16, 2025 at 4:30 p.m. (Eastern Time), or as soon thereafter as practicable. Please feel free to direct any questions or comments concerning this request to Marishka DeToy, Esq. of Goodwin Procter LLP at (617) 570-1926. The Company understands that the staff of the United States Securities and Exchange Commission will consider this request as confirmation by the Company that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. INHIBIKASE THERAPEUTICS, INC. By: /s/ Milton H. Werner, Ph.D. Name: Milton H. Werner, Ph.D. Title: President and Chief Executive Officer cc: Danielle Lauzon, Goodwin Procter LLP Marishka DeToy, Goodwin Procter LLP